Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

av Shibasaki, Noboru, Yamasaki, Toshinari, Kanno, Toru, Arakaki, Ryuichiro, Sakamoto, Hiromasa, Utsunomiya, Noriaki, Inoue, Takahiro, Tsuruyama, Tatsuaki, Nakamura, Eijiro, Ogawa, Osamu, Kamba, Tomomi
I publikationen PLoS One (2015)

CCL2 as a potential therapeutic target for clear cell renal cell carcinoma

av Arakaki, Ryuichiro, Yamasaki, Toshinari, Kanno, Toru, Shibasaki, Noboru, Sakamoto, Hiromasa, Utsunomiya, Noriaki, Sumiyoshi, Takayuki, Shibuya, Shinsuke, Tsuruyama, Tatsuaki, Nakamura, Eijiro, Ogawa, Osamu, Kamba, Tomomi
I publikationen Cancer Med (2016)

Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti‐angiogenic therapy

av Yamasaki, Toshinari, Kamba, Tomomi, Kanno, Toru, Inoue, Takahiro, Shibasaki, Noboru, Arakaki, Ryuichiro, Yamada, Tomomi, Kondo, Keiichi, Kamoto, Toshiyuki, Nishiyama, Hiroyuki, Ogawa, Osamu, Nakamura, Eijiro
I publikationen Cancer Sci (2012)

Functional and genomic characterization of patient‐derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma

av Sakamoto, Hiromasa, Yamasaki, Toshinari, Sumiyoshi, Takayuki, Takeda, Masashi, Shibasaki, Noboru, Utsunomiya, Noriaki, Arakaki, Ryuichiro, Akamatsu, Shusuke, Kobayashi, Takashi, Inoue, Takahiro, Kamba, Tomomi, Nakamura, Eijiro, Ogawa, Osamu
I publikationen Cancer Med (2020)